

Images in Clinical Tropical Medicine

Plasmodium malariae—Repeat Light Microscopy when Molecular Testing is Not Available

Serena X. Zhang,^{1*} Karl C. Kronmann,² and Michael J. Kavanaugh²

¹Department of Internal Medicine, Naval Medical Center Portsmouth, Portsmouth, Virginia; ²Department of Infectious Disease, Naval Medical Center Portsmouth, Portsmouth, Virginia

A 31-year-old previously healthy male required hospital admission after returning from rural Cameroon 10 weeks prior with severe myalgia, chills, 72 hours cyclical fever to 103.1°F, and tachycardia for 2 weeks. He endorsed adherence to atovoquone/proguanil chemoprophylaxis and recalled no exposure to lake or stream water. He was ill appearing, but without focal abnormalities. Laboratory findings were significant for leukopenia 2,900 cells/uL, thrombocytopenia 82,000 cells/uL, aspartate aminotransferase 316 units/L, and alanine aminotransferase 400 units/L. Initial three light microscopy (LM) and rapid diagnostic test (RDT) with BinaxNOW (Alere, Inc., Waltham, MA) were negative. However, continued investigation eventually revealed *Plasmodium malariae* on the fourth LM in its pathognomonic “rosette” schizont (Figure 1) and “band”—developing gametocyte (Figure 2).¹ The patient was treated effectively with artemether/lumefantrine. *Plasmodium malariae* infections were once considered a rare and mild illness largely because of poor sensitivity on RDT and LM.^{1–3} However, recent improvement in polymerase chain reaction (PCR) technique increased the identification of *P. malariae* that might have been misdiagnosed as fever of unknown origin.^{3–5} Although there were reports of late onset and recrudescence despite adherent chemoprophylaxis, subsequent treatment has been paradoxically successful with




FIGURE 1. “Rosette” schizont. This figure appears in color at www.ajtmh.org.




FIGURE 2. “Band”—developing gametocyte. This figure appears in color at www.ajtmh.org.

the same medication.^{3,5,6} Because of *P. malariae*'s long senescent periods, recrudescence ability, and low parasite burden, clinicians must have high clinical suspicion and consider repeating LM when resource is limited or using PCR for diagnosis.⁷

Received July 18, 2018. Accepted for publication September 12, 2018.

Copyright statement: We are military service members. This work was prepared as part of our official duties. Title 17 U.S.C. 105 provides that “Copyright protection under this title is not available for any work of the United States Government.” Title 17 U.S.C. 101 defines a United States Government work as a work prepared by a military service member or employee of the United States Government as part of that person's official duties.

Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the United States Government.

Authors' addresses: Serena X. Zhang, Department of Internal Medicine, Naval Medical Center Portsmouth, Portsmouth, VA, E-mail: s.zhang9876@gmail.com. Karl C. Kronmann and Michael J. Kavanaugh, Department of Infectious Disease, Naval Medical Center Portsmouth, Portsmouth, VA, E-mails: karl.c.kronmann.mil@mail.mil and michael.j.kavanaugh.mil@mail.mil.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. Mueller I, Zimmerman PA, Reeder JC, 2007. *Plasmodium malariae* and *Plasmodium ovale*—the ‘bashful’ malaria parasites. *Trends Parasitol* 23: 278–283.

*Address correspondence to Serena Zhang, LT, US Navy, Department of Internal Medicine, Naval Medical Center Portsmouth, 620 John Paul Jones Cir, Portsmouth, VA 23708. E-mail: s.zhang9876@gmail.com

2. Yerlikaya S, Campillo A, Gonzalez IJ, 2018. A systematic review: performance of rapid diagnostic tests for the detection of *Plasmodium knowlesi*, *Plasmodium malariae*, and *Plasmodium ovale* monoinfections in human blood. *J Infect Dis* 218: 265–276.
3. Vinetz JM, Li J, Mccutchan TF, Kaslow DC, 1998. *Plasmodium malariae* infection in an asymptomatic 74-year-old Greek woman with splenomegaly. *New Engl J Med* 338: 367–371.
4. Phuong M, Lau R, Ralevski F, Boggild AK, 2014. Sequence-based optimization of a quantitative real-time PCR assay for detection of *Plasmodium ovale* and *Plasmodium malariae*. *J Clin Microbiol* 52: 1068–1073.
5. Yavne Y, Leshem E, Paran Y, Nadir E, Weinberger M, Stein M, Petersiel N, Yahav D, Grossman T, Schwartz E, 2017. *Plasmodium malariae* in Israeli travelers: a nationwide study. *Clin Infect Dis* 65: 1516–1522.
6. Maguire JD, Sumawinata IW, Masbar S, Laksana B, Prodjodipuro P, Susanti I, Sismadi P, Mahmud N, Bangs MJ, Baird JK, 2002. Chloroquine-resistant *Plasmodium malariae* in south Sumatra, Indonesia. *Lancet* 360: 58–60.
7. Hedelius R, Fletcher JJ, Glass WF, Susanti AI, Maguire JD, 2011. Nephrotic syndrome and unrecognized *Plasmodium malariae* infection in a US navy sailor 14 years after departing Nigeria. *J Travel Med* 18: 288–291.